Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
S. Kovacic, M. Bakran.
Genetic susceptibility to atherosclerosis.
Stroke Res Treat, 2012 (2012), pp. 1-5
[2.]
F.W. Luthardt, E. Keitges.
Chromosomal syndromes and genetic disease.
Encyclopedia of Life Sciences, (2001), pp. 1-11
[3.]
R.D. Aatre, S.M. Day.
Psychological issues in genetic testing for inherited cardiovascular diseases.
Circ Cardiovasc Genet, 4 (2011), pp. 81-90
[4.]
J.A. Johnson, L.H. Cavallari, A.L. Beitelshees, et al.
Pharmacogenomics: application to the management of cardiovascular disease.
Clin Pharmacol Ther, 90 (2011), pp. 519-531
[5.]
FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. Disponible en: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm. Fecha de acceso: marzo de 2010.
[6.]
J.D. Nunnelee.
Review of an article: The international Warfarin Pharmacogenetics Consortium.
Estimation of the warfarin dose with clinical and pharmacogenetic data NEJM, 360 (2009), pp. 753-764
[7.]
Gene Tests Medical Genetics Information Resource (database online). Copyright UoW, Seattle. 1993-2012. Disponible en: http://www.genetests.org
[8.]
C.J. O’Donnell, E.G. Nabel.
Genomics of cardiovascular disease.
N Engl J Med, 365 (2011), pp. 2098-2109
Copyright © 2013. Socidad Colombiana de Cardiología y Cirugía Cardiovascular